■“国际浆液性细胞病理学报告系统”(TIS)包括五个诊断类别:非诊断(ND),恶性肿瘤(NFM)阴性,不确定意义的非典型性(AUS),可疑恶性肿瘤(SFM),恶性(MAL)。该研究是根据新提出的TIS对积液细胞学样品进行重新分类,以计算每个类别的恶性肿瘤(ROM)风险并进行性能分析。
该研究是在印度北部的一家三级护理机构进行的回顾性观察性研究。检索2013年6月至2021年7月病例的临床资料,并由两名细胞病理学家对病例进行审查。根据拟议的TIS系统将所有病例重新分为五类。
■在8年的时间内,共有2318名患者被纳入研究,1614例(69.6%)胸腔积液细胞学检查,612例(26.4%)腹腔积液细胞学检查,92例(3.9%)心包积液细胞学检查。根据TIS指南将所有积液细胞学涂片重新分类为ND,NFM,AUS,SFM,MAL为4(0.17%),1756(75.75%),12(0.51%),57(2.46%),489例(21.11%),分别,ROM是25%,17.9%,66.7%,75.4%,96.5%,分别,对于类别。
■除了简单,easy,和用户友好的系统,TIS对每个类别都有风险分层和ROM的好处。TIS系统提出了一个分层方案,将积液细胞学分为明确的类别,因此,假阳性和假阴性病例的可能性较小。
UNASSIGNED: The \"international system for reporting serous fluid cytopathology\"(TIS) consists of five diagnostic categories: nondiagnostic (ND), negative for malignancy (NFM), atypia of undetermined significance (AUS), suspicious for malignancy (SFM), and malignant (MAL). The study was conducted to reclassify effusion cytology samples according to the newly proposed TIS to calculate the risk of malignancy (ROM) for each category and to conduct performance analysis.
UNASSIGNED: The study was a retrospective observational study conducted at a tertiary care institution in North India. Clinical data of the cases from June 2013 to July 2021 were retrieved and the cases were reviewed by two cytopathologists. All cases were reclassified according to the proposed TIS system into five categories.
UNASSIGNED: A total of 2318 patients were included in the study over a time span of 8 years, and 1614 (69.6%) cases of pleural effusion cytology, 612 (26.4%) cases of peritoneal effusion cytology, and 92 (3.9%) cases of pericardial effusion cytology were included. All effusion cytology smears were recategorized as per TIS guidelines into ND, NFM, AUS, SFM, and MAL with 4 (0.17%), 1756 (75.75%), 12 (0.51%), 57 (2.46%), and 489 (21.11%) cases, respectively, and ROM was 25%, 17.9%, 66.7%, 75.4%, and 96.5%, respectively, for the categories.
UNASSIGNED: Besides being a simple, easy, and user-friendly system, TIS has the benefit of risk stratification and ROM for each category. The TIS system proposed a tiered scheme, which places the effusion cytology into well-defined categories, and therefore has lesser chances of false-positive and false-negative cases.